Cerecor CEO and leadership

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

James 'Jamie' Harrell is a SENIOR VP & PRINCIPAL at NSCI GROUP at Nsci Group, Inc; Exec VP:Mktg & Investor Relations at CERECOR INC.; and Chief Commercial Officer at CERECOR INC. and is based in Baltimore, Maryland. She has worked as VP/Gen Mgr:Specialty Pharmaceuticals at Covidien (Medtronic Minimally Invasive Therapies Group), Exec VP:Mktg & External Communications at CERECOR INC., and VP:Marketing at Medimmune. James attended Samford University between 1987 and 1990.

Chris Sullivan is an Interim CFO at CERECOR INC. and is based in Baltimore, Maryland. He has worked as VP:Finance at CERECOR INC., Sr. Manager at EY, and Corporate Controller at OPGEN INC. Chris studied at University of Maryland between 2001 and 2005.

Garry Neil joined Arena Pharmaceuticals, Inc.as Member of the Board of Directors in 2017. Garry Neil joined as CSO of Medgenics in September 2013. Prior to joining Medgenics, Dr. Neil was a Partner at Apple Tree Partners, a life sciences private equity fund. Prior to joining Apple Tree Partners in 2012, he was Corporate VP of Science & Technology at Johnson & Johnson, and Group President at Johnson & Johnson Pharmaceutical Research and Development. Prior to joining Johnson & Johnson in 2002, he held senior positions at AstraZeneca, EMD Pharmaceuticals and Merck KGaA. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases gained initial or expanded approvals. Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He serves on the Boards of Reagan Udall Foundation and the Foundation for the U.S. National Institutes of Health (NIH), and is a member of the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board.

Dr. Wilkins has 16 years of clinical research experience. Prior to joining Ceptaris, he served as Vice President of Worldwide Clinical Development: Oncology and Immunology at Cephalon.Before joining Cephalon, he was Senior Vice President of Clinical Development with Ception Therapeutics, a biologics company (acquired by Cephalon). He entered the pharmaceutical industry joining GlaxoSmithKline after 10 years as a family medicine physician.Dr. Wilkins was co-founder and Chief Executive Officer of TriValley Primary Care, a large multi-center primary group in northern Bucks and Montgomery Counties in Pennsylvania.Dr. Wilkins earned his M.D. from Temple University and a B.S. from Bucknell University.

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.